IL23A and psoriasis: Tildrakizumab, an anti-IL-23 antibody, acts at the cellular level and is thought to improve the skin lesions of psoriasis by inhibiting the differentiation and proliferation of Th17 cells and the pathogenic conversion of Tregs to Th17 cells (27).